Friedman Billings Cuts Biogen to 'Underperform'

Analyst Jonathan Aschoff thinks sales of Biogen's multiple sclerosis drug may weaken in the face of Pfizer's deal with Serono, a maker of a rival treatment

Friedman Billings downgraded Biogen (BGEN ) to underperform from market perform.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.